Dopamine D1 and D3 receptors are differentially involved in cue-elicited cocaine seeking.
Environmental cues previously associated with reinforcing drugs can play a key role in relapse to drug seeking behaviors in humans. The mesocorticolimbic dopamine system plays a critical role in cocaine-induced neurobiological changes. Dopamine D1 and D3 receptors modulate locomotor-stimulant and positive reinforcing effects of cocaine, and cue-induced reinstatement of cocaine-seeking. Moreover, activation of the extracellular signal-regulated kinase (ERK) induced by acute cocaine administration is regulated by both D1 and D3 receptors. How D1 and D3 receptors modulate the acquisition and extinction of cue-elicited cocaine seeking behavior and associated changes in the MAPK signaling pathway in different brain regions, however, remains unclear. In the present study, we found that D1 receptor mutant mice failed to acquire conditioned place preference (CPP) while D3 receptor mutant mice show delayed CPP extinction compared with wild-type mice. Moreover, ERK, but not the c-jun N-terminal kinase and p38, is activated in wild-type and D3 receptor mutant mice but not in D1 receptor mutant mice following CPP acquisition. D3 receptor mutant mice also exhibit sustained ERK activation compared with wild-type mice following extinction training. Our results suggest that D1 and D3 receptors differentially contribute to learned association between cues and the rewarding properties of cocaine by regulating, at least in part, ERK activation in specific areas of the brain.
Chen
Liping
L
Department of Anesthesia and Critical Care, The University of Chicago, Chicago, Illinois, USA.
Xu
Ming
M
D000818:Animals; D001921:Brain / Q000201:enzymology; D019970:Cocaine-Related Disorders / Q000378:metabolism* / Q000523:psychology; D003213:Conditioning, Psychological; D003463:Cues; D004789:Enzyme Activation; D005108:Extinction, Psychological; D048049:Extracellular Signal-Regulated MAP Kinases / Q000378:metabolism; D048031:JNK Mitogen-Activated Protein Kinases / Q000378:metabolism; D051379:Mice; D008817:Mice, Mutant Strains; D017447:Receptors, Dopamine D1 / Q000235:genetics / Q000502:physiology*; D050637:Receptors, Dopamine D3 / Q000235:genetics / Q000502:physiology*; D048051:p38 Mitogen-Activated Protein Kinases / Q000378:metabolism
D017447:Receptors, Dopamine D1; D050637:Receptors, Dopamine D3; D048049:Extracellular Signal-Regulated MAP Kinases; D048031:JNK Mitogen-Activated Protein Kinases; D048051:p38 Mitogen-Activated Protein Kinases
Annu Rev Pharmacol Toxicol. 2002;42:135-63
11807168
Trends Neurosci. 2006 Dec;29(12):695-703
17084911
Nat Neurosci. 2005 Feb;8(2):212-9
15657599
Brain Res. 2001 Feb 16;892(1):86-93
11172752
Neuropsychopharmacology. 2010 Jan;35(1):217-38
19710631
Curr Opin Pharmacol. 2005 Feb;5(1):9-19
15661620
Nature. 1999 Jul 22;400(6742):371-5
10432116
Eur J Neurosci. 2005 Mar;21(5):1385-93
15813948
Brain Res. 2002 Mar 1;929(1):15-25
11852027
Neuron. 1997 Oct;19(4):837-48
9354330
J Neurosci. 2006 Dec 20;26(51):13287-96
17182779
Prog Neurobiol. 1998 Dec;56(6):613-72
9871940
Neuron. 2005 Sep 15;47(6):873-84
16157281
Psychopharmacology (Berl). 2004 Nov;176(3-4):459-65
15138757
Neuroreport. 2000 Aug 3;11(11):2395-9
10943692
Nat Rev Neurosci. 2004 Mar;5(3):173-83
14976517
J Neurophysiol. 1998 Jul;80(1):1-27
9658025
J Neurosci. 2004 Aug 11;24(32):7167-73
15306650
Mol Neurobiol. 2004 Feb;29(1):1-14
15034219
Cell. 1994 Nov 18;79(4):729-42
7954836
J Neurochem. 2001 Jan;76(2):401-12
11208903
Nat Rev Neurosci. 2004 Jun;5(6):483-94
15152198
Brain Res. 2000 Jan 3;852(1):198-207
10661513
Br J Pharmacol. 2008 May;154(2):261-74
18311189
Psychopharmacology (Berl). 2000 Dec;153(1):31-43
11255927
Annu Rev Neurosci. 2006;29:565-98
16776597
Proc Natl Acad Sci U S A. 1988 Jul;85(14):5274-8
2899326
Neuron. 2009 Feb 12;61(3):425-38
19217379
J Neurosci. 2007 Nov 28;27(48):13140-50
18045908
J Neurosci. 2000 Dec 1;20(23):8701-9
11102476
Mol Pharmacol. 2004 May;65(5):1293-301
15102958
J Neurosci. 2008 Jun 4;28(23):6046-53
18524910
J Neurosci. 1996 Oct 15;16(20):6579-91
8815934
Neuroscience. 2006;137(2):699-706
16289883
Mol Psychiatry. 2007 Feb;12(2):120-50
17160066
Eur J Neurosci. 1998 May;10(5):1676-86
9751140
Cell. 1994 Dec 16;79(6):945-55
8001143
J Neurosci. 1999 Oct 1;19(19):8685-95
10493769
Science. 1987 Sep 4;237(4819):1219-23
2820058
Mol Interv. 2006 Dec;6(6):339-44
17200461
J Neurosci. 2004 Jul 28;24(30):6686-92
15282271
Neuropsychopharmacology. 2008 Jan;33(1):166-80
17805308
Behav Neurosci. 2008 Feb;122(1):129-39
18298256
J Neurosci. 2008 May 28;28(22):5671-85
18509028
Eur J Neurosci. 2005 Oct;22(7):1741-50
16197514
Nat Neurosci. 2005 Nov;8(11):1431-6
16251982
J Neurochem. 2007 Jan;100(1):225-41
17101033
Neuropsychopharmacology. 2006 Dec;31(12):2660-8
16407894
J Neurosci. 2004 Mar 31;24(13):3344-54
15056714
Proc Natl Acad Sci U S A. 2006 Feb 21;103(8):2932-7
16473939
Neuroimage. 2008 Feb 1;39(3):1266-73
18024160
Nat Neurosci. 2004 Apr;7(4):389-97
15034590
J Neurochem. 2005 Dec;95(5):1481-94
16219028
J Neurosci. 2000 Oct 1;20(19):7489-95
11007908
Nat Rev Neurosci. 2007 Nov;8(11):844-58
17948030
Neuropharmacology. 2004;47 Suppl 1:3-13
15464121
Neuroscience. 2005;134(1):247-60
15951121
Physiol Rev. 1998 Jan;78(1):189-225
9457173
Neuroreport. 1995 Nov 27;6(17):2314-6
8747144
Proc Natl Acad Sci U S A. 1994 Dec 20;91(26):12564-8
7809078
J Neurosci. 2005 Apr 13;25(15):3932-9
15829645
Brain Res Brain Res Rev. 2005 Jul;49(1):77-105
15960988
Brain Res Brain Res Rev. 1998 May;26(2-3):236-42
9651537
Addict Biol. 2007 Sep;12(3-4):227-462
17678505
Eur J Neurosci. 2006 Jul;24(1):261-9
16882022
J Neurosci. 2000 Jan 15;20(2):798-805
10632609
Neuron. 2005 May 19;46(4):661-9
15944133
Am J Psychiatry. 2005 Aug;162(8):1403-13
16055761
Proc Natl Acad Sci U S A. 2005 Jan 11;102(2):491-6
15608059
Neurosci Biobehav Rev. 2004 Jan;27(8):739-49
15019424